Search results
Results from the WOW.Com Content Network
Although no clinical development took place, Axovant held its IPO in June 2015 and raised $315 million, [4] the largest biotech IPO ever, [9] based on new phase IIB trials that were more promising. [10] The lock-up period against reselling stock was reduced to an unusually short 90 days for hedge funds that showed interest in the IPO. [11]
[citation needed] Avalanche went public through an IPO in 2014, raising $102 million. [6] In 2015, co-founder Tom Chalberg stepped down as CEO following Phase IIa trial results that were labeled as "iffy". [7] In May 2016, Avalanche acquired Annapurna Therapeutics and changed its name to Adverum Biotechnologies. [8]
This page was last edited on 3 February 2024, at 22:53 (UTC).; Text is available under the Creative Commons Attribution-ShareAlike 4.0 License; additional terms may apply.
Need help? Call us! 800-290-4726 Login / Join. Mail
The IPO raised $604.3 million and eclipsed the $373 million raised by Allogene Therapeutics in October, which is the largest biotech since Axovant Sciences' $363 million IPO in 2015.
For premium support please call: 800-290-4726 more ways to reach us
This was the largest Canadian biotech IPO in more than a decade. [5] By alphabetical order, Zymeworks is the last company on the Toronto Stock Exchange. In May 2019, Zymeworks announced that GSK has expanded its 2016 licensing and collaboration agreement for the research, development and commercialization of bispecific antibodies across ...
For premium support please call: 800-290-4726 more ways to reach us